Compound Evidence File
#EC-2026-0430
Sustanon 400
Filed under Injectable Oils. The bureau holds 98 laboratory returns for this compound from 36 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
36 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 10 Dec 2025 | 27 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 10.0 | 10.0 | 12 Feb 2026 | 4 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 4 | 10.0 | 9.9 | 10.0 | 1 May 2026 | 8 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 9.9 | 10.0 | 16 Jan 2026 | 18 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 3 | 10.0 | 9.9 | 10.0 | 26 May 2026 | 2 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 10.0 | 10.0 | 10.0 | 25 Apr 2026 | 6 Jul 2026 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 10.0 | 10.0 | 10.0 | 24 Apr 2025 | 24 Apr 2025 |
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 3 May 2026 | 13 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Dec 2025 | 17 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 3 | 9.9 | 9.9 | 10.0 | 3 Feb 2026 | 7 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 15 Nov 2025 | 13 Apr 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 9.9 | 14 May 2026 | 11 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 9.9 | 18 Dec 2025 | 6 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jan 2026 | 28 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 2 | 9.6 | 9.4 | 9.8 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.9 | 8.4 | 9.5 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.8 | 8.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 7 | 8.7 | 7.3 | 9.7 | 24 May 2026 | 24 May 2026 |
| NextGen HealthCASE #VI-2026-0604 | X | 1 | 8.7 | 8.7 | 8.7 | 13 Jun 2025 | 13 Jun 2025 |
| TCICASE #VI-2026-0650 | X | 1 | 8.6 | 8.6 | 8.6 | 20 Jun 2025 | 20 Jun 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 8 | 8.4 | 7.5 | 10.0 | 24 May 2026 | 24 May 2026 |
| Aavant ResearchCASE #VI-2026-0831 | X | 1 | 8.4 | 8.4 | 8.4 | 27 Feb 2025 | 27 Feb 2025 |
| AKS ChemCASE #VI-2026-0313 | X | 1 | 8.2 | 8.2 | 8.2 | 2 Jul 2025 | 2 Jul 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 6.5 | 5.9 | 7.1 | 20 Jun 2025 | 25 May 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 2 | 6.5 | 4.6 | 8.3 | 20 Jun 2025 | 26 Jan 2026 |
| Diju Peptides Wellness and CoCASE #VI-2026-0724 | X | 1 | 6.5 | 6.5 | 6.5 | 2 Apr 2025 | 2 Apr 2025 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 4 | 6.4 | 4.6 | 7.8 | 11 Jun 2025 | 24 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 1 | 6.2 | 6.2 | 6.2 | 21 May 2025 | 21 May 2025 |
| HazelCASE #VI-2026-0392 | X | 1 | 5.7 | 5.7 | 5.7 | 28 Mar 2025 | 28 Mar 2025 |
| Biolongevity LabsCASE #VI-2026-0442 | X | 2 | 5.1 | 4.7 | 5.4 | 13 Feb 2025 | 20 May 2026 |
| Amplified AminoCASE #VI-2026-0748 | X | 1 | 4.6 | 4.6 | 4.6 | 3 Jul 2025 | 3 Jul 2025 |
| NuLife PeptidesCASE #VI-2026-0980 | X | 1 | 1.4 | 1.4 | 1.4 | 14 Jan 2025 | 14 Jan 2025 |
| HybiopeptidesCASE #VI-2026-0305 | X | 1 | 0.2 | 0.2 | 0.2 | 14 Jan 2025 | 14 Jan 2025 |
| Marvel PeptideCASE #VI-2026-0507 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Sustanon 400 alone.